Exceptional launch for Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease – Verona Pharma
Verona Pharma plc announces preliminary unaudited net product sales for the fourth quarter and full year ended December 31, 2024, and provides a corporate update. “2024 was another… read more.
